Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Geron Corp (GERN)

Geron Corp (GERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 891,678
  • Shares Outstanding, K 636,913
  • Annual Sales, $ 76,990 K
  • Annual Income, $ -174,570 K
  • EBIT $ -174 M
  • EBITDA $ -185 M
  • 60-Month Beta 0.66
  • Price/Sales 11.75
  • Price/Cash Flow N/A
  • Price/Book 3.06

Options Overview Details

View History
  • Implied Volatility 201.65% ( +67.13%)
  • Historical Volatility 72.63%
  • IV Percentile 94%
  • IV Rank 37.32%
  • IV High 521.72% on 05/29/24
  • IV Low 11.12% on 07/01/24
  • Put/Call Vol Ratio 0.28
  • Today's Volume 379
  • Volume Avg (30-Day) 717
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 85,667
  • Open Int (30-Day) 85,834

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.04
  • Number of Estimates 6
  • High Estimate -0.03
  • Low Estimate -0.05
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +55.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1700 +17.95%
on 04/16/25
1.6300 -15.34%
on 03/31/25
-0.2700 (-16.36%)
since 03/28/25
3-Month
1.1700 +17.95%
on 04/16/25
3.0900 -55.34%
on 02/05/25
-1.5100 (-52.25%)
since 01/29/25
52-Week
1.1700 +17.95%
on 04/16/25
5.3400 -74.16%
on 06/12/24
-2.7600 (-66.67%)
since 04/29/24

Most Recent Stories

More News
Why Geron Stock Is Plummeting Today

Geron (NASDAQ: GERN) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m. ET and had been down as much as 38.7% earlier in the session.

GERN : 1.3800 (-1.43%)
Geron (GERN) Q4 2024 Earnings Call Transcript

GERN earnings call for the period ending December 31, 2024.

GERN : 1.3800 (-1.43%)
Geron: Q4 Earnings Snapshot

Geron: Q4 Earnings Snapshot

GERN : 1.3800 (-1.43%)
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street

These biotech companies’ strategic advancements are setting them up for long-term success.

RPRX : 32.71 (+0.52%)
JNJ : 155.91 (+0.36%)
VRTX : 503.50 (+1.41%)
SNDX : 13.70 (+2.09%)
ABBV : 193.51 (+0.61%)
GERN : 1.3800 (-1.43%)
RHHBY : 40.6600 (+0.37%)
PFE : 23.79 (+3.21%)
NTLA : 8.20 (-3.30%)
BMY : 49.22 (+1.57%)
BIIB : 120.17 (+0.88%)
Geron Stock Rallies More Than 60% in a Year: Here's Why

For Geron Corporation GERN, 2024 was a transformational year as it saw the FDA approval and commercial launch of Rytelo (imetelstat) for the treatment of low- to intermediate-1 risk myelodysplastic syndromes...

PBYI : 3.04 (+2.01%)
CSTL : 19.85 (-1.19%)
GERN : 1.3800 (-1.43%)
HALO : 60.82 (+0.41%)
Geron (GERN) Q3 2024 Earnings Call Transcript

GERN earnings call for the period ending September 30, 2024.

GERN : 1.3800 (-1.43%)
Geron: Q3 Earnings Snapshot

Geron: Q3 Earnings Snapshot

GERN : 1.3800 (-1.43%)
Is This Penny Stock With 55% Upside A Buy Now?

This biotech company currently has an approved product on the market. However, there is more to the story than meets the eye.

$SPX : 5,560.83 (+0.58%)
GERN : 1.3800 (-1.43%)
Geron (GERN) Q2 2024 Earnings Call Transcript

GERN earnings call for the period ending June 30, 2024.

GERN : 1.3800 (-1.43%)
Geron: Q2 Earnings Snapshot

Geron: Q2 Earnings Snapshot

GERN : 1.3800 (-1.43%)

Business Summary

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic...

See More

Key Turning Points

3rd Resistance Point 1.4667
2nd Resistance Point 1.4333
1st Resistance Point 1.4067
Last Price 1.3800
1st Support Level 1.3467
2nd Support Level 1.3133
3rd Support Level 1.2867

See More

52-Week High 5.3400
Fibonacci 61.8% 3.7471
Fibonacci 50% 3.2550
Fibonacci 38.2% 2.7629
Last Price 1.3800
52-Week Low 1.1700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar